SSR 180575
Alternative Names: SSR180575Latest Information Update: 05 May 2009
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Class Acetamides; Heart failure therapies; Indoles; Neuroprotectants; Small molecules
- Mechanism of Action TSPO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Heart failure; Rheumatic disorders
- Discontinued Diabetic neuropathies
Most Recent Events
- 29 Apr 2009 Discontinued - Phase-II for Diabetic neuropathies in USA (PO)
- 12 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Neurological disorders pharmacodynamics section
- 01 Mar 2005 Phase-I clinical trials in Congestive heart failure in France (unspecified route)